S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Charles River Laboratories International (CRL) Stock Forecast & Price Target

$229.90
-2.44 (-1.05%)
(As of 04/17/2024 ET)

Charles River Laboratories International Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Analysts' Consensus Price Target

$253.23
10.15% Upside
High Forecast$290.00
Average Forecast$253.23
Low Forecast$205.00
TypeCurrent Forecast
4/19/23 to 4/18/24
1 Month Ago
3/20/23 to 3/19/24
3 Months Ago
1/19/23 to 1/19/24
1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$253.23$249.64$233.31$267.75
Predicted Upside10.15% Upside14.07% Upside17.77% Upside21.44% Upside
Get Charles River Laboratories International Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

CRL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Charles River Laboratories International Stock vs. The Competition

TypeCharles River Laboratories InternationalMedical CompaniesS&P 500
Consensus Rating Score
2.64
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside10.06% Upside929.43% Upside12.25% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/18/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$240.00 ➝ $290.00+10.18%
2/15/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$260.00 ➝ $265.00+8.44%
2/15/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$215.00 ➝ $250.00+4.30%
2/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$270.00 ➝ $290.00+20.99%
2/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$270.00 ➝ $280.00+15.93%
2/15/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$252.00 ➝ $268.00+10.96%
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$220.00 ➝ $205.00+19.19%
9/25/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$212.00 ➝ $209.00+5.15%
9/22/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$280.00 ➝ $275.00+38.78%
9/22/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$245.00 ➝ $230.00+16.07%
5/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $250.00+31.01%
5/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $255.00+30.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:42 AM ET.

CRL Price Target - Frequently Asked Questions

What is Charles River Laboratories International's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Charles River Laboratories International stock is Moderate Buy based on the current 4 hold ratings and 7 buy ratings for CRL. The average twelve-month price prediction for Charles River Laboratories International is $253.23 with a high price target of $290.00 and a low price target of $205.00. Learn more on CRL's analyst rating history.

Do Wall Street analysts like Charles River Laboratories International more than its competitors?

Analysts like Charles River Laboratories International less than other Medical companies. The consensus rating score for Charles River Laboratories International is 2.64 while the average consensus rating score for medical companies is 2.68. Learn more on how CRL compares to other companies.

Is Charles River Laboratories International being downgraded by Wall Street analysts?

Over the previous 90 days, Charles River Laboratories International's stock had 1 downgrade by analysts.

Does Charles River Laboratories International's stock price have much upside?

According to analysts, Charles River Laboratories International's stock has a predicted upside of 14.73% based on their 12-month stock forecasts.

What analysts cover Charles River Laboratories International?

Charles River Laboratories International has been rated by Argus, Citigroup, Evercore ISI, Guggenheim, JPMorgan Chase & Co., Robert W. Baird, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:CRL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners